Key facts
- This page summarizes Paula Cloghessy's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Feb 2023, 16:42.
Paula Cloghessy - 03 Feb 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Executive Vice President, Chief People Officer
- Issuer ticker
- MCRB
- Reported as of
- 03 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Feb 2023, 16:42:15 UTC
- Prior SEC filing
- 06 Jul 2022
- Next SEC filing
- 31 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, attorney-in-fact for Paula Cloghessy
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paula Cloghessy filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 07 Feb 2023.
Change
- Previous filing in this sequence was filed on 06 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MCRB
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +47,500
- Change %
- Price
- $0.000000
- Shares after
- 47,500
- Date
- 03 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,500
- Exercise price
- Footnotes
- F1, F2
MCRB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +95,000
- Change %
- Price
- $0.000000
- Shares after
- 95,000
- Date
- 03 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 95,000
- Exercise price
- $5.50
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Footnote F2
The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.
Footnote F3
The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
SEC remarks
Executive Vice President, Chief People Officer